DOI: https://doi.org/10.22141/2224-0551.14.0.2019.165521

Features of management of children with persistent diarrhea and Candida albicans overgrowth

S.L. Nyankovskyy, О.S. Nyankovska, Yu.V. Pakulova-Trotska, H.Z. Vivcharivska, V.D. Shaidych, O.M. Horayska, L.V. Zastavna, Z.V. Tomkiv

Abstract


Background: to evaluate the effectiveness of Mutaflor in children from 1 to 4 years of age with a diagnosis of functional gastrointestinal disorders in the form of persistent diarrhea against the background of proven overgrowth of Candida albicans. Materials and methods. The study involved 32 children aged 1 to 4 years with a diagnosis of functional gastrointestinal disorders in the form of persistent diarrhea with proven overgrowth of Candida albicans. Duration of administration of the probiotic agent Mutaflor at a dose of 1 ml of suspension once a day was 15 days. Thirty children completed the follow-up, two patients were excluded from the analysis of results due to non-adherence to treatment protocol. Results. All children had an overgrowth of Candida albicans at baseline. After 15 days of treatment, Candida albicans was detected in the stools of 12 children (40 %), in 11 of them (36.7 %), it was detected in the amount of 104 CFUs, and in one patients (3.3 %) — 103 CFUs indicating that the strain Escherichia coli Nissle 1917 was quite effective for intestinal candidiasis. Conclusions. The use of Mutaflor (Escherichia coli Nissle 1917 probiotic strain) in children with persistent diarrhea against the background of Candida albicans overgrowth contributes to the reduction of diarrhea, colic, abdominal distension, vomiting, episodes of crying/anxiety and poor sleep in children, normalizes intestinal biocenosis.


Keywords


children; functional gastrointestinal disorders; diarrhea; Candida albicans

References


Bischoff S. Gut health: a new objective in medicine? BMC Med. 2011 Mar 14;9:24. doi: 10.1186/1741-7015-9-24.

Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016 Nov 3;167(4):915-932. doi: 10.1016/j.cell.2016.10.027.

Keunen K, van Elburg RM, van Bel F, Benders MJ. Impact of nutrition on brain development and its neuroprotective implications following preterm birth. Pediatr Res. 2015 Jan;77(1-2):148-55. doi: 10.1038/pr.2014.171.

Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci. 2011 Jul 13;12(8):453-66. doi: 10.1038/nrn3071.

Lyte M. Microbial endocrinology in the microbiome-gutbrain axis: How bacterial production and utilization of neurochemicals influence behaviour. PLoS Pathog. 2013;9(11):e1003726. doi: 10.1371/journal.ppat.1003726.

Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med. 2016 Apr 27;8(1):51. doi: 10.1186/s13073-016-0307-y.

Henker J, Laass MW, Blokhin BM, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J. 2008 Jun;27(6):494-9. doi: 10.1097/INF.0b013e318169034c.

Nissle A. Weiteres uber Grundlagen und Praxis der Mutaflorbehandiung. Dtsch med Wochenschr. 1925;51(44):1809-1813. doi: 10.1055/s-0028-1137292.

Nissle A. Über die Grundlagen einer neuen ursächlichen Bekämpfung der pathologischen Darmflora. Dtsch med Wochenschr 1916;42(39):1181-1184. doi: 10.1055/s-0028-1135392.

Nissle A. Die antagonistische Behandlung chronischer Darmstörungen mit Colibakterien. Med Klin. 1918;(2):29-33.

Krammer HJ, Kämper H, von Bünau R, et al. Probiotic drug therapy with Escherichia coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3807 patients. Z Gastroenterol. 2006 Aug;44(8):651-6. doi: 10.1055/s-2006-926909.

Rohrenbach J, Matthess A, Maier R, et al. Escherichia coli strain Nissle 1917 (EcN) in children: results of a prospective survey in 668 patients. Kinder Jugendarzt. 2007;(3):164-167.

Henker J, Blokhin BM, Bolbot YK, et al. The probiotic E. coli Nissle 1917 stops acute diarrhoea in infants and toddlers. Eur J Pediatr. 2007 Apr;166(4):311-8. doi: 10.1007/s00431-007-0419-x.

Tromm A, Niewerth U, Khoury M, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) for the treatment of collagenous colitis: first results of an open_label trialZ Gastroenterol. 2004 May;42(5):365-9. doi: 10.1055/s-2004-812709.

Lodinová-Zádniková R, Sonnenborn U. Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate. 1997;71(4):224-32. doi: 10.1159/000244421.

Gronbach K, Eberle U, Müller M, et al. Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect Immun. 2010 Jul;78(7):3036-46. doi: 10.1128/IAI.00218-10.

Lodinova-Zadnikova R, Tlaskalova_Hogenova H, Sonnenborn U. Local and serum antibody response in fullterm and premature infants after artificial colonization of the intestine with E. coli strain Nissle 1917 (Mutaflor®). Pediatr Allergy Immunol. 1992;3(1):43-48. doi: 10.1111/j.1399-3038.1992.tb00026.x.

Lodinová-Zádniková R, Sonnenborn U. Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate. 1997;71(4):224-32. doi: 10.1159/000244421.

Cukrowska B, Lodinova_Zadnikova R, Enders C, Sonnenborn U, Schulze J, Tlaskalová-Hogenová H. Specific proliferative and antibody response of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol. 2002 Feb;55(2):204-9.

Schütz E. Behandlung von Darmerkrankungen mit Mutaflor. Fortschr Med. 1989;107:599-602.

Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis. 2012 Apr;27(4):467-74. doi: 10.1007/s00384-011-1363-9.

Shirtliff ME1, Peters BM, Jabra-Rizk MA. Cross‐kingdom interactions: Candida albicans and bacteria. FEMS Microbiol Lett. 2009 Oct;299(1):1-8. doi: 10.1111/j.1574-6968.2009.01668.x.

Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012 Jun 13;486(7402):207-14. doi: 10.1038/nature11234.

Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):497-505. doi: 10.1038/nrgastro.2014.40.

Kraft-Bodi E, Jørgensen MR, Keller MK, Kragelund C, and Twetman S. Effect of Probiotic Bacteria on Oral Candida in Frail Elderly. J Dent Res. 2014;94(9 Suppl):181S-186S. doi: 10.1177/0022034515595950.

Cabral DJ, Wurster JI, Flokas ME, et al. The salivary microbiome is consistent between subjects and resistant to impacts of short-term hospitalization. Sci Rep. 2017 Sep 8;7(1):11040. doi: 10.1038/s41598-017-11427-2.

Cabral DJ, Penumutchu S, Norris C, Morones-Ramirez JR, Belenky P. Мicrobial competition between Escherichia coli and Candida albicans reveals a soluble fungicidal factor. Microb Cell. 2018 Mar 7;5(5):249-255. doi: 10.15698/mic2018.05.631.

Sonnenborn U. Escherichia coli strain Nissle 1917—from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol Lett. 2016 Oct;363(19). pii: fnw212. doi: 10.1093/femsle/fnw212.

Coyte KZ, Schluter J, and Foster KR. The ecology of themicrobiome: Networks, competition, and stability. Science. 2015 Nov 6;350(6261):663-6. doi: 10.1126/science.aad2602.

Vazquez-Rodriguez A, Vasto-Anzaldo XG, Barboza Perez D, et al. Microbial Competition of Rhodotorula ucilaginosa UANL-001L and E. coli increase biosynthesis of Non-Toxic Exopolysaccharide with Applications as a Wide-Spectrum Antimicrobial. Sci Rep. 2018 Jan 15;8(1):798. doi: 10.1038/s41598-017-17908-8.

Chen Q, Zhu Z, Wang J, et al. Probiotic E. coli Nissle 1917 biofilms on silicone substrates for bacterial interference against pathogen colonization. Acta Biomater. 2017 Mar 1;50:353-360. doi: 10.1016/j.actbio.2017.01.011.

Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999 Aug 21;354(9179):635-9.

Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol. 1997 Dec;25(4):653-8.

Hancock V, Dahl M, Klemm P. Probiotic Escherichia coli strain Nissle 1917 outcompetes intestinal pathogens during biofilm formation. J Med Microbiol. 2010 Apr;59(Pt 4):392-9. doi: 10.1099/jmm.0.008672-0.






Copyright (c) 2019 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта